Last update May 13, 2019
We do not have alternatives for ラウレス4.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
ラウレス4 is Macrogol Lauril Ether in Japanese.Is written in other languages:
ラウレス4 is also known as
ラウレス4 belongs to this group or family:
Main tradenames from several countries containing ラウレス4 in its composition:
|Molecular weight||583 (400 - 600)||daltons|
|VD||0.26 - 1.2||l/Kg|
|T½||0.9 - 1.5||hours|
Write us at firstname.lastname@example.org
e-lactancia is a resource recommended by Asociación Pro Lactancia Materna (APROLAM) of Mexico
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
A mixture of macrogol ethers. An anionic surfactant detergent with sclerosing properties on varicose veins.
Administration by local injections in the vein to be sclerosed.
It contains 5% alcohol.
Since the last update we have not found any published data on its excretion in breast milk.
After local injections, low plasma levels have been detected in some patients (FDA 2010). Its moderately high molecular weight, large volume of distribution and short half-life (AEMPS 2017, FDA 2010) would hinder transfer into breastmilk.
Several experts believe that the use of this medication is probably compatible during breastfeeding (Briggs 2017, Hale 2017 p784).
Due to the lack of accurate pharmacokinetic data and given that after 5 half-lives of elimination (5 T½), 97% of a substance is eliminated from the body (Anderson 2016), it may be prudent, in order to minimize any possible exposure, to stop breastfeeding between 7 - 8 hours after the last sclerosing injection. However, the manufacturer advises a waiting period of 2 to 3 days (AEMPS 2017) which seems excessive since it is not based on the pharmacokinetics of the product.
See below the information of this related product: